US Patent No: 4,599,230

Number of patents in Portfolio can not be more than 2000

Synthetic hepatitis B virus vaccine including both T cell and B cell determinants

1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Chemically synthesized polypeptides include amino acid residue sequences that substantially correspond to the amino acid residue sequences of T cell and B cell determinant portions of a natural, pathogen-related protein, in particular, a hepatitis B virus surface antigen (HBsAg). When administered to a host alone, as polymers or as carrier-bound conjugates, the polypeptides induce the proliferation of thymus-derived cells in hosts primed against hepatitis B virus.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
THE SCRIPPS RESEARCH INSTITUTELA JOLLA, CA943

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chisari, Frank V Del Mar, CA 2 180
Milich, David R Escondido, CA 20 366

Cited Art Landscape

Patent Info (Count) # Cites Year
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2)
4,415,491 Synthetic vaccine peptide epitomes of hepatitis B surface antigen 35 1980
4,483,793 Dimeric oligopeptides as heptenic epitopic sites for hepatitis 6 1982
 
INSTITUT PASTEUR (1)
4,428,941 Nucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby 55 1981

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (11)
5,807,552 Compositions for conferring immunogenicity to a substance and uses thereof 11 1995
6,656,471 HIV-specific T-cell induction 9 1999
7,306,804 HIV-specific T-cell induction 0 2003
7,847,084 species and strains 4 2003
7,316,907 14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types 9 2004
7,627,938 Tapered hollow metallic microneedle array assembly and method of making and using the same 13 2004
7,803,363 bacteria 1 2007
7,709,205 14-3-3 Zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer type 0 2007
8,076,470 species and strains 4 2010
8,283,458 species and strains 3 2011
8,722,871 VMP-like sequences of pathogenic borrelia species and strains 0 2012
 
The Scripps Research Institute (9)
5,939,524 Platelet GPIII P1.sup.A1 and P1.sup.A2 epitopes, their preparation and use 9 1991
5,709,995 Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses 19 1994
5,780,036 Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus 11 1995
5,932,224 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus 8 1995
6,607,727 Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus 5 1996
7,220,420 Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses 3 1997
7,763,589 Compositions and methods for treating intracellular diseases 0 1999
6,919,203 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus 0 2001
7,368,118 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus 1 2005
 
CONNAUGHT LABORATORIES LIMITED (8)
5,922,562 Nucleic acids encoding transferrin receptors 1 1994
6,020,125 Basal body rod protein FlgF of campylobacter 1 1995
6,015,688 Transferrin receptor genes 2 1995
6,008,326 Transferrin receptor antibodies 0 1995
5,922,323 Transferrin receptor genes and immunogenic compositions derived therefrom 1 1995
5,922,841 Recombinantly produced transferrin receptor of haemophilus 3 1995
5,837,250 Adjuvant compositions 3 1995
7,118,749 Transferrin receptor genes 1 2002
 
Medeva Holdings B.V. (7)
6,020,167 Composition used as a therapeutic agent against chronic viral hepatic diseases 12 1994
6,022,543 Hepatitis B surface antigen vaccine 6 1994
6,589,530 Hepatitis B surface antigen vaccine 0 1995
6,117,653 Hepatitis B surface antigen vaccine 7 1995
6,110,706 Hepatitis B surface antigen vaccine 3 1995
6,100,065 Hepatitis B surface antigen vaccine 1 1995
6,072,049 Hepatitis B surface antigen vaccine 6 1995
 
AVENTIS PASTEUR LIMITED (5)
6,764,682 Adjuvant compositions containing more than one adjuvant 2 1994
6,361,779 Transferrin receptor genes 0 1996
6,358,727 Haemophilus transferrin receptor genes 0 1996
6,290,971 Adjuvant compositions comprising a mineral salt and another immunostimulating compound 2 1997
6,262,016 Transferrin receptor genes 0 1997
 
EPIMMUNE INC. (5)
6,419,931 Compositions and methods for eliciting CTL immunity 24 1994
6,322,789 HLA-restricted hepatitis B virus CTL epitopes 7 1995
7,572,882 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions 1 2000
7,462,354 Method and system for optimizing minigenes and peptides encoded thereby 0 2001
7,611,713 Inducing cellular immune responses to hepatitis B virus using peptide compositions 1 2003
 
LONGHORN VACCINES & DIAGNOSTICS, LLC (5)
8,821,885 Immunogenic compositions and methods 0 2008
8,652,782 Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids 0 2011
8,293,467 Biological specimen collection and transport system and methods of use 4 2011
8,415,330 Biological specimen collection and transport system and method of use 1 2012
8,669,240 Biological specimen collection and transport system and method of use 0 2013
 
AKSHAYA BIO INC. (4)
8,029,803 Chimeric antigens for eliciting an immune response 1 2003
8,025,873 Chimeric antigens for eliciting an immune response 1 2004
8,007,805 Chimeric antigens for breaking host tolerance to foreign antigens 1 2004
8,465,745 Chimeric antigens for eliciting an immune response 0 2011
 
New York Blood Center, Inc. (4)
4,847,080 Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers 29 1985
4,861,588 Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers 25 1986
5,204,096 Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers 25 1989
5,565,548 Pre-S gene coded peptide hepatitis B immunogens and synthetic lipid vesicle carriers 23 1993
 
VLP BIOTECH (4)
7,320,795 Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof 2 2003
7,144,712 Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof 1 2003
7,883,843 Hepatitis virus core proteins as vaccine platforms and methods of use thereof 0 2004
7,811,576 Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof 0 2008
 
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (3)
7,923,001 Compositions and methods for diagnosing and treating urinary tract infections 0 2008
8,668,911 vaccine compositions and methods of using the same 0 2010
8,133,496 Compositions and methods for diagnosing and treating urinary tract infections 0 2011
 
UNIVERSITE LIBRE DE BRUXELLES (3)
7,947,450 Device, kit and method for pulsing biological samples with an agent and stabilising the sample so pulsed 2 2008
8,067,172 Device, kit and method for pulsing biological samples with an agent and stabilising the sample so pulsed 0 2010
8,206,916 Device, kit and method for pulsing biological samples with an agent and stabilising the sample so pulsed 0 2011
 
CEL-SCI CORPORATION (2)
5,652,342 Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same 11 1994
6,096,315 Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same 2 1995
 
DEVELOPMENT CENTER FOR BIOTECHNOLOGY (2)
8,110,197 heat-labile enterotoxin 0 2007
8,088,394 heat-labile enterotoxin 0 2008
 
ITERATIVE THERAPEUTICS, INC. (2)
8,163,289 Methods and compositions involving polymeric immunoglobulin fusion proteins 0 2008
7,897,729 Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors 1 2008
 
NEUROLOGIX, INC. (2)
8,017,385 Use of apotosis inhibiting compounds in degenerative neurological disorders 0 2005
8,071,563 Glutamic acid decarboxylase (GAD) chimera and methods of use 0 2009
 
BAYLOR RESEARCH INSTITUTE (1)
8,518,410 Fusion protein with HIV antigen 0 2010
 
BEALE STREET 143 INVEST APS (1)
7,097,837 Synthetic vaccine agents 8 2002
 
CHIRON CORPORATION (1)
4,722,840 Hybrid particle immunogens 109 1985
 
Epimunne Inc. (1)
8,741,576 Heteroclitic analogs and related methods 0 2002
 
GFF GESELLSCHAFT ZUR FORDERUNG DER INDUSTRIEORIENTIERTEN FORSCHUNG (1)
6,596,278 Immunological response potentiation process 3 1995
 
GGMJ TECHNOLOGIES, L.L.C. (1)
5,348,867 Expression of proteins on bacterial surface 57 1991
 
H. LUNDBECK A/S (1)
7,135,181 Method for down-regulation of amyloid 9 2001
 
Institute of Immunology Co., Ltd. (1)
5,019,386 Hepatitis B vaccine 18 1988
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
5,019,384 Immunonodulating compositions and their use 25 1989
 
OSE PHARMA INTERNATIONAL SA (1)
7,252,829 HLA binding peptides and their uses 5 1998
 
PHARMEXA INC. (1)
6,689,363 Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions 20 1999
 
POWDERJECT VACCINES, INC. (1)
6,881,723 Nucleic acid constructs 0 1999
 
Praxis Biologics, Inc. (1)
5,785,973 Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines 29 1995
 
STATENS SERUM INSTITUT (1)
8,105,614 Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails 0 2007
 
Symbicom Aktiebolag (1)
6,610,838 P13 antigens from Borrelia 2 1998
 
THE GENERAL HOSPITAL CORPORATION (1)
8,476,227 Methods of activating a melanocortin-4 receptor pathway in obese subjects 0 2010
 
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (1)
5,827,654 Basal body rod protein genes of campylobacter 1 1995
 
The Green Cross Corporation (1)
4,694,074 Process for the purification of HBsAg 3 1985
 
United Biomedical, Inc. (1)
5,106,726 Synthetic peptides specific for the detection of antibodies to HCV 72 1990